APA (7th ed.) Citation

Yang, M., Sachdev, R., Stargardter, M., Tosh, J., & Vioix, H. (2022). EE160 Tepotinib for the Treatment of Adult Patients with Metastatic Non-Small Cell Lung Cancer Harboring METEX14 Skipping Alterations: A US Cost-Effectiveness Analysis. Value in Health, 25(7), S365. https://doi.org/10.1016/j.jval.2022.04.409

Chicago Style (17th ed.) Citation

Yang, M., R. Sachdev, M. Stargardter, J. Tosh, and H. Vioix. "EE160 Tepotinib for the Treatment of Adult Patients with Metastatic Non-Small Cell Lung Cancer Harboring METEX14 Skipping Alterations: A US Cost-Effectiveness Analysis." Value in Health 25, no. 7 (2022): S365. https://doi.org/10.1016/j.jval.2022.04.409.

MLA (9th ed.) Citation

Yang, M., et al. "EE160 Tepotinib for the Treatment of Adult Patients with Metastatic Non-Small Cell Lung Cancer Harboring METEX14 Skipping Alterations: A US Cost-Effectiveness Analysis." Value in Health, vol. 25, no. 7, 2022, p. S365, https://doi.org/10.1016/j.jval.2022.04.409.